Arrowstreet Capital Limited Partnership lowered its position in shares of Ralliant Corporation (NYSE:RAL – Free Report) by 15.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,463,778 shares of the company’s stock after selling 265,500 shares during the quarter. Arrowstreet Capital Limited Partnership owned approximately 1.31% of Ralliant worth $60,879,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of RAL. Bank of Nova Scotia lifted its stake in shares of Ralliant by 571.1% in the 1st quarter. Bank of Nova Scotia now owns 162,400 shares of the company’s stock valued at $6,754,000 after purchasing an additional 138,200 shares during the period. Sei Investments Co. grew its position in shares of Ralliant by 193.7% in the 1st quarter. Sei Investments Co. now owns 182,342 shares of the company’s stock valued at $7,583,000 after purchasing an additional 120,248 shares during the period. Walleye Capital LLC bought a new stake in shares of Ralliant during the first quarter worth $4,525,000. First Trust Advisors LP increased its holdings in Ralliant by 7.7% during the 1st quarter. First Trust Advisors LP now owns 95,937 shares of the company’s stock worth $3,990,000 after purchasing an additional 6,897 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Ralliant by 60.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,314,834 shares of the company’s stock valued at $54,669,000 after buying an additional 496,171 shares during the last quarter.
Ralliant Stock Up 0.5%
Shares of NYSE:RAL opened at $69.75 on Tuesday. The business’s 50 day simple moving average is $66.65 and its two-hundred day simple moving average is $53.94. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $75.41. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The firm has a market cap of $7.81 billion and a P/E ratio of -6.38.
Ralliant Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio is currently -1.83%.
Wall Street Analyst Weigh In
RAL has been the subject of several recent research reports. Royal Bank Of Canada increased their price target on Ralliant from $64.00 to $71.00 and gave the company a “sector perform” rating in a research report on Thursday, July 16th. Oppenheimer increased their price target on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Wall Street Zen downgraded Ralliant from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Vertical Research cut shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective on the stock. in a research note on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $73.00.
Get Our Latest Report on Ralliant
About Ralliant
Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Further Reading
- Five stocks we like better than Ralliant
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.
